Q: I am looking to increase my Healthcare sector and recommendations be at this time for stocks or ETF in this sector?
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: Hi, great job my portfolio is up, thanks.
I bought GUD for sector, management, cash position, growth (safety) etc.
They finally made an acquisition which looks ok.(no homerun?) still down ,bought at $8.50
Looks like an important quarter in March,if it is good all should be ok, if not ,it will not have the big cash backstop that it did in the past. Won’t this be a problem?
Getting a little impatient, if it is only a so-so or down quarter, is it not time to seriously consider an alternative? Or would you give it “another”3-5 years?
Thanks,
I bought GUD for sector, management, cash position, growth (safety) etc.
They finally made an acquisition which looks ok.(no homerun?) still down ,bought at $8.50
Looks like an important quarter in March,if it is good all should be ok, if not ,it will not have the big cash backstop that it did in the past. Won’t this be a problem?
Getting a little impatient, if it is only a so-so or down quarter, is it not time to seriously consider an alternative? Or would you give it “another”3-5 years?
Thanks,
Q: Medtronic has released earnings slightly better than expected and the stock has dropped, your thoughts please.
Thank You
Peter
Thank You
Peter
Q: Can I have your guide on how to invest in pharmaceutical stocks? Please share a few names to start with. Also please comment on TEVA's latest result. Thank you.
Q: Based on the research available to you, do you see reasonable upside potential for Global Blood and Sarepta? Would you choose one over the other? Do you see any major downside risks for either company? Thanks again for your support>
Q: When do they report ?
Q: Good morning, I have owned GILD for a while now and am finally above water on the investment. I am thinking of exiting and investing in a US health care focused ETF. Which would you suggest?
thanks
thanks
Q: Hi,
BHC will be reporting in about 7 days or so , if I am not mistaken.
May I please get your opinion on this stock.
Thanks,
BHC will be reporting in about 7 days or so , if I am not mistaken.
May I please get your opinion on this stock.
Thanks,
Q: Is the dividend sustainable (7%) and what do they think of the long term prospects of this company?
Q: Why is BDX taking a hit again today?
Is it still worth holding or better to sell while I still have a profit?
If I sell - any suggestions for replacements?
Take the number of credits required for these three questions.
Is it still worth holding or better to sell while I still have a profit?
If I sell - any suggestions for replacements?
Take the number of credits required for these three questions.
Q: Contemplating acquiring Pharma ETF with world wide exposure with emphasis on diabetes for long term hold, Obviously management fees & performance, size for liquidity a concern. Currently own 5 -6 % position in "GUD"
Garry
Garry
Q: Good morning:
Thoughts on this company please . Is it a buy?
Thx
Mark
Thoughts on this company please . Is it a buy?
Thx
Mark
Q: Big price jump today, but no news, and no chatter on stockhouse; any idea why?
Q: I'd appreciate your take on Premier Health which no analyst seems to cover. I discovered it while searching for other publicly-traded companies that use OSCAR as a platform for their electronic medical record (EMR) offerings.
WELL Health has been very clear that they are in the hunt for OSCAR-related assets - it so happens that PHGI has three of them (JunoEMR, KindredEHR and ClinicAid). They also have a couple of other assets that WELL would like to have or planning to develop (e.g. 4 clinics, a patient portal, telemedicine, a medical billing app, 2 pharmacies, interactive kiosks, etc.).
WELL Health has been very clear that they are in the hunt for OSCAR-related assets - it so happens that PHGI has three of them (JunoEMR, KindredEHR and ClinicAid). They also have a couple of other assets that WELL would like to have or planning to develop (e.g. 4 clinics, a patient portal, telemedicine, a medical billing app, 2 pharmacies, interactive kiosks, etc.).
-
Danaher Corporation (DHR)
-
Medtronic plc. (MDT)
-
Stryker Corporation (SYK)
-
iShares U.S. Medical Devices ETF (IHI)
Q: Hi, I've held ISRG for a few years now, am up 25% but was honestly expecting more. It's traded largely sideways since Sept of 2018. 5i and I both seem to have similar (great) expectations for this company, but they just can't break $620 or so.
I'm tempted to dump ISRG and pick up some IHI which includes a number of other seemingly great companies that are on my watch list. However, I keep thinking ISRG is on the brink of its next big leg up. From my research, I have ISRG at the bottom of its long term channel - which if it holds - would have stock price growth at 40% from here...
Help me decide: hold (even add) to ISRG, or dump it and pick up IHI. Perhaps a bit of column A and column B?
Cam
I'm tempted to dump ISRG and pick up some IHI which includes a number of other seemingly great companies that are on my watch list. However, I keep thinking ISRG is on the brink of its next big leg up. From my research, I have ISRG at the bottom of its long term channel - which if it holds - would have stock price growth at 40% from here...
Help me decide: hold (even add) to ISRG, or dump it and pick up IHI. Perhaps a bit of column A and column B?
Cam
Q: Hi 5i Team,
I bought Merck a few days ago aiming to balance my portfolio, yesterday the reaction of the market was negative , a 5% drop, after they reported earning combined with announcement of spinning off three divisions,.
Was the spin off is that negative?
What is your outlook of this company.
Thank you for your professional and helpful advice as always.
I bought Merck a few days ago aiming to balance my portfolio, yesterday the reaction of the market was negative , a 5% drop, after they reported earning combined with announcement of spinning off three divisions,.
Was the spin off is that negative?
What is your outlook of this company.
Thank you for your professional and helpful advice as always.
Q: Good afternoon team,
I'm considering making a small purchase (2%) of CRH Do you see this stock continuing its current climb and possibly recapturing the magic from its big run a few years ago?
Thanks, Tristan.
I'm considering making a small purchase (2%) of CRH Do you see this stock continuing its current climb and possibly recapturing the magic from its big run a few years ago?
Thanks, Tristan.
Q: In your Feb 7 response to Jerry on PRN after referring to recent strong momentum you say “markets obviously think there is potential here, but the company now needs to start delivering on that potential.”
I would argue that PRN started delivering on the potential long ago – the company received FDA approval Aug 2019 after a successful clinical trial; PRN successfully listed on NASDAQ last fall; the company announced in early January this year a deal and partnership with RadNet, the largest network of outpatient imaging centres in the US; and recently PRN raised US$ 40 million in an equity financing and retired all bank debt ahead of schedule. PRN is now well positioned to scale the business without further dilution.
I recognize there remains commercialization risk and there is reimbursement risk and revenues are essentially non-existent at this early stage but what we have here is a very experienced very competent management team that has done it before with NOVADAQ. Significantly, the CEO Arun and his team are not doing this because they need to money. They will not rush it they will do it right. I think you have mentioned in the past that this is one of the best small cap situations to invest in – assuming you can deal with the volatility and risk.
I would argue that PRN started delivering on the potential long ago – the company received FDA approval Aug 2019 after a successful clinical trial; PRN successfully listed on NASDAQ last fall; the company announced in early January this year a deal and partnership with RadNet, the largest network of outpatient imaging centres in the US; and recently PRN raised US$ 40 million in an equity financing and retired all bank debt ahead of schedule. PRN is now well positioned to scale the business without further dilution.
I recognize there remains commercialization risk and there is reimbursement risk and revenues are essentially non-existent at this early stage but what we have here is a very experienced very competent management team that has done it before with NOVADAQ. Significantly, the CEO Arun and his team are not doing this because they need to money. They will not rush it they will do it right. I think you have mentioned in the past that this is one of the best small cap situations to invest in – assuming you can deal with the volatility and risk.
Q: In a largely positive market GH is not doing well. Why?
Should I sell and buy the best 3 US growth companies that you recommend. Thanks.
Klaus
Should I sell and buy the best 3 US growth companies that you recommend. Thanks.
Klaus
Q: Kindly provide your opinion of this Company. Is the valuation reasonable? I noticed it is the largest weighting in the BMO's ZUH ETF.
Best, Don
Best, Don